Marker Therapeutics, Inc. — Q2 2021 Form 10-Q
Business context and reporting period. This clinical-stage immuno-oncology company develops MultiTAA T-cell therapies and peptide-based vaccines. The unaudited quarter and six-month periods ended June 30, 2021 are compared with the corresponding 2020 periods. The company reported no product sales and remains dependent on financing to advance development.
Financial performance and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $0 | $467,000 | $0 | $467,000 |
| Research and development expense | $7.35 million | $4.28 million | $12.99 million | $8.09 million |
| General and administrative expense | $3.56 million | $2.55 million | $6.70 million | $5.37 million |
| Operating expenses | $10.91 million | $6.82 million | $19.69 million | $13.47 million |
| Net loss | $10.91 million | $6.34 million | $19.69 million | $12.83 million |
| Basic and diluted loss per share | $0.13 | $0.14 | $0.28 | $0.28 |
| Cash used in operating activities | Not separately stated for the quarter | $15.91 million | $8.40 million |
There were no meaningful revenue-based margins to report. For the six months, investing activities used $0.78 million, financing activities provided $52.56 million, and cash increased $35.87 million. Cash and cash equivalents were $57.22 million at June 30, 2021, versus $21.35 million at year-end 2020; working capital was $54.36 million versus $18.01 million.
Total liabilities were $17.23 million, including $12.13 million of operating lease liabilities. The filing does not report borrowings or other financial debt. The company raised $52.6 million net through a March public offering of 32.28 million shares; common shares outstanding increased from 50.7 million at December 31, 2020 to 83.1 million at June 30, 2021.
Material changes and management commentary
- Six-month net loss increased 53% year over year, principally reflecting expanded R&D and clinical activity, higher staffing and infrastructure costs, and manufacturing-facility expenses. R&D increased 61%; G&A increased 25%.
- The prior-year periods included $467,000 of grant income for clinical supplies related to a breast cancer trial; no grant income was recorded in 2021. Lower interest income also contributed to the year-over-year loss change.
- The manufacturing facility entered service in January 2021. Management attributed increased depreciation, rent and utilities, and process-development costs partly to the facility and program expansion.
- Management estimated that June 30 cash would fund operating and capital needs into the first quarter of 2023, based on current plans and assumptions. It cautioned that spending plans or development needs could change and require capital sooner. Substantial losses are expected to continue for years; no substantial product revenue is expected in the near term.
Clinical outlook, risks and contingencies
- The company completed the safety lead-in for its company-sponsored MT-401 Phase 2 trial in post-transplant AML in June 2021; the remainder of the trial began in July. It planned to enroll about 20 patients, activate additional U.S. sites in Q4 2021, and report active-disease-arm results in Q1 2022. Manufacturing for the trial was expected to begin at its cGMP facility in Q3 2021.
- Management described partner-conducted MultiTAA trials across AML/MDS, pancreatic cancer, breast cancer, ALL, lymphoma, multiple myeloma and sarcoma. It reported generally good tolerability in trials to date, with no observed cytokine release syndrome or neurotoxicity; these are early clinical observations, not proof of efficacy.
- Development, regulatory approval, manufacturing, financing and commercialization remain uncertain. Failure to raise capital could force delays or reductions in programs; equity financing may dilute shareholders, while debt or partnerships could impose restrictions or require rights to be surrendered. Management said COVID-19 had no expected material long-term liquidity effect based on its current assessment, but clinical operations and capital access could still be affected.
- A broker’s FINRA arbitration seeks approximately $1.6 million in compensation, $335,000 in interest and approximately $600,000 in attorney fees, alleging entitlement under a 2017 placement-agent agreement for 2018 transactions. The hearing concluded and post-hearing briefs were filed; a decision was pending. Management stated it was not party to proceedings likely to have a material adverse effect on the business.
- The filing reported no material changes to the risk factors in the 2020 Form 10-K and no material off-balance-sheet arrangements. Management considered disclosure controls effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether actual cash burn and clinical/manufacturing spending remain consistent with the stated first-quarter 2023 runway estimate.
- MT-401 trial enrollment, site activation, manufacturing readiness, and the timing and interpretation of planned results.
- Clinical evidence, safety, and regulatory progress across company- and partner-sponsored programs.
- Potential dilution and future funding needs, including the effect of additional equity, debt, or collaboration financing.
- Outcome and financial exposure from the pending arbitration, including any attorney-fee award.